Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Short-term increases in inhaled corticosteroids unlikely to help exacerbations of asthma
Vault Navigation
Short-term increases in inhaled corticosteroids unlikely to help exacerbations of asthma
Is it clinically effective and safe to increase doses of inhaled corticosteroids (ICS) as part of a patient‐initiated action plan for home management of exacerbations in children and adults with persistent asthma?
Evidence from double‐blind trials of adults and children with mild to moderate asthma suggests there is unlikely to be an important reduction in the need for oral steroids from increasing a patient’s ICS dose at the first sign of an asthma exacerbation.
Other clinically important benefits and potential harms of increased doses of ICS compared with keeping the dose stable cannot be ruled out due to wide confidence intervals, risk of bias in the trials, and assumptions made to permit synthesis.
The included studies, conducted between 1998 and 2018, reflect evolving clinical practice and study methods, and the data did not support thorough investigation of effect modifiers such as baseline dose, fold increase, asthma severity and timing.
The review does not include recent evidence from pragmatic, unblinded studies that suggest a benefit of larger dose increases in those with poorly controlled asthma.
People with asthma may experience exacerbations, or “attacks”, during which their symptoms worsen and additional treatment is required. Written action plans sometimes advocate a short‐term increase in the dose of ICS at the first sign of an exacerbation, to reduce the severity of the attack and prevent the need for oral steroids or hospital admission.
Kew KM, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2022;9:CD007524. This review contains 9 trials with a total of 1923 participants.